# VNRX earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/VNRX) · [Earnings tab](https://www.lopjlb.com/stock/VNRX?tab=earnings)

Updated: 2026-11-12T07:07:33

Quarters analyzed: 8

## Cross-quarter narrative

Across eight quarterly CallCards VolitionRx’s trajectory shifted from early‑stage veterinary growth and nascent human‑program licensing to tangible human‑product revenue and broader commercial partnerships. 2024 Q3 highlighted 100% veterinary revenue growth and licensing talks, while Q4 added multi‑country test rollout, cost cuts and a slate of on‑track milestones but flagged automation risk and financial uncertainty. 2025 Q1 introduced first human sales, a 44% YoY revenue lift, deeper licensing pipelines and CE‑Mark approvals, followed by Q2’s emphasis on $600 B‑plus licensing opportunities and a Taiwan lung‑cancer study progressing toward ESMO data. Mid‑year 2025 saw strategic alliances with Werfen and Hologic, a 32% revenue rise, and advanced Capture‑Seq technology. By Q4 the company secured first orders for Nu.Q Cancer and NETs assays and continued expense reductions. 2026 quarters reported a 300% YoY revenue jump (driven by deferred revenue), sizable cash raises, headcount cuts, and ongoing advances in Capture‑Seq, lung‑cancer reimbursement and feline‑cancer testing.  Overall, revenue, licensing activity and cost efficiency improved markedly, while early automation concerns faded and commercialization milestones moved from on‑track to delivery.

## Latest CallCard · Q2

VolitionRx reports Q2 revenue flat YoY but H1 up 112%; OpEx down 32% with 27% headcount cut; advancing Nu.Q NETs lateral flow, Capture-Seq, lung cancer reimbursement, and feline vet test; $2.8M cash after $5.3M equity raises.','tone': {'mgmt': 0.2, 'mgmt_rationale': 'Management emphasizes scientific

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q2:** VolitionRx reports Q2 revenue flat YoY but H1 up 112%; OpEx down 32% with 27% headcount cut; advancing Nu.Q NETs lateral flow, Capture-Seq, lung cancer reimbursement, and feline vet test; $2.8M cash after $5.3M equity raises.','tone': {'mgmt': 0.2, 'mgmt_rationale': 'Management emphasizes scientific
- **2026 Q1:** VNRX Q1 2026: Rev $1M (+300% YoY) on deferred rev; cash $3.1M after $7.3M raise; progress Vet (feline, auto), NETs (sepsis, trauma, finger-prick), Discover (100 clients, rNuQ), Cancer (France reimb), Capture-Seq (>99% ctDNA); licensing talks; no 2026 rev guide.','tone': {'mgmt': 0.3, 'mgmt_rationale
- **2025 Q4:** VolitionRx reported strong Q4 growth, first orders for Nu.Q Cancer and NETs assays, new licensing deals, reduced operating expenses and highlighted upcoming milestones including a feline cancer payment and further licensing agreements.
- **2025 Q3:** VolitionRx signed two partnership agreements (Werfen for APS, Hologic for Nu.Q Discover co-marketing), grew Q3 revenue 32% to $0.6M, cut operating expenses 10% YoY, advanced Capture-Seq liquid biopsy tech with 180-fold enrichment, and progresses lung cancer studies in France and Taiwan while managin
- **2025 Q2:** VolitionRx advances Nu.Q platform commercialization with first human revenue, progressing licensing talks with >10 companies ($600B+ combined value), Taiwan lung cancer screening study on track for ESMO interim data, targeting cash neutrality in 2025 via licensing upfronts and cost cuts.','tone': {'
- **2025 Q1:** VNRX Q1 2025: revenue up 44% YoY with first human product sales, op-ex down 35%, cash burn halved; targeting cash neutrality for 2025; >10 licensing talks, pivotal lung cancer study enrolling, Nu.Q NETs CE Mark sales in Europe, Nu.Q Discover pharma study launched, $6.25M convertible note post-quarte
- **2024 Q4:** VolitionRx reports strong 2024 growth, expanded Vet test to 20+ countries, new licensing momentum and aims for cash‑neutral 2025 despite lacking revenue guidance.
- **2024 Q3:** VolitionRx reports 100% YTD vet revenue growth, 110k Nu.Q tests sold, advancing human lung cancer and sepsis programs with licensing talks underway. Cash neutral 2025 goal maintained.

## Theme arcs

- **Revenue growth** (improving): From 100% vet growth to 300% YoY increase with human product sales
- **Licensing activity** (improving): Multiple talks in 2024, >10 deals in 2025, $600B+ pipeline
- **Operating expense reduction** (improving): Op‑Ex fell 23% YoY in Q4 2024, 35% YoY in Q1 2025, continued cuts in 2026
- **Human assay commercialization** (new): First human sales, CE‑Mark NETs, Nu.Q Cancer/NETs orders, co‑marketing deals
- **Geographic expansion** (improving): Vet test in 20+ countries, Taiwan study, France reimbursement
- **Automation and scale** (resolved): Early risk around manual ELISA and Fuji automation, no later mentions suggests risk mitigated
- **Capital strategy** (stable): Shift from R&D to commercialization funding, equity raises in 2026

## Fear persistence

- **Financial** [resolved]: Financial uncertainty highlighted in Q4 2024 but not repeated in later calls
- **Market adoption** [resolved]: Adoption concerns noted in Q4 2024, absent from subsequent updates
- **Funding** [resolved]: Funding reliance mentioned in Q4 2024, later calls focus on equity raises without explicit fear

## Guidance path

2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:vague → 2026 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/VNRX`